Tivic Health (TIVC) announced that shareholders approved key proposals to carry out the company’s strategic transformation at its annual meeting on June 30. The approved proposals included the issuance of equity as payment for its worldwide exclusive license agreement for Entolimod and Entolasta. Shareholders also approved the company’s issuance of equity in accordance with previously announced financing arrangements.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TIVC:
- Tivic Health Systems Appoints Lisa Wolf as CFO
- Tivic Health Systems Amends License Agreement with Statera
- Tivic Health completes optimization study for vagus nerve stim device
- Tivic Health Completes Optimization Study for ncVNS Device
- Tivic Health files to sell 8.44M shares of common stock for holders